DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/23/2025 13:01 PDT] DexCom, Inc. (NASDAQ:DXCM), Down By 100% ($82.85) From $82.85 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/23/2025 07:21 PDT] DXCM Expected to Trade Down After Bearish Patterns Develop
• [06/19/2025 07:52 PDT] DXCM, Expected to Trade Lower After Bearish Insider Trading
• [06/13/2025 08:01 PDT] DXCM Expected to Trade Down After Bearish Patterns Develop
• [05/29/2025 07:29 PDT] DXCM, Expected to Trade Lower After Bearish Insider Trading